Phaseline

Targets › MC2R

MC2R (Adrenocorticotropic hormone receptor): drug programs, companies and trials

5 programs from 5 companies in 7 trials: 3 Phase 2, 2 Phase 3, 1 Phase 4, 1 Phase 1; Genitourinary, Ophthalmology, Other; next expected readout Dec 2026.

G protein-coupled receptor for corticotropin/ACTH, primarily expressed in adrenal cortex where it plays a key role in the regulation of adrenocortical function. Upon activation, couples to G(s) protein, stimulating adenylate cyclase and activating the cAMP-dependent signaling pathway, the MAPK cascade as well as the PKA pathway, leading to steroidogenic factor 1/NR5A1-mediated transcriptional activation. (UniProt, Q01718)

Open in Phaseline: the race on MC2R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Toyos ClinicCorticotropin
Melanocortin receptor 2 agonist
MC2RPhase 4Autoimmune DiseasesFeb 2028
Mao JianhuaCorticotropin
Melanocortin receptor 2 agonist
MC2RPhase 3Nephrotic Syndrome in ChildrenDec 2026
Crinetics PharmaceuticalsAtumelnant
Melanocortin 2 receptor (MC2R/ACTH receptor) antagonist
MC2RPhase 3Congenital Adrenal HyperplasiaMay 2027
Sheffield Children's NHS Foundation TrustCosyntropin
Melanocortin receptor 2 agonist
MC2RPhase 2Adrenal Suppression–
Peter y. LiuCosyntropin
Melanocortin receptor 2 agonist
MC2RPhase 1Sleep Restriction–

Conditions

Congenital Adrenal Hyperplasia (3) Autoimmune Diseases (1) Adrenal Suppression (1) Sleep Restriction (1) Nephrotic Syndrome in Children (1)

Modalities

small molecule (4), protein or peptide (1)

Companies

Crinetics Pharmaceuticals (1) Toyos Clinic (1) Sheffield Children's NHS Foundation Trust (1) Peter y. Liu (1) Mao Jianhua (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.